|Place of Origin:||China|
|Model Number:||1ml: 80mg, 0.5ml:40mg|
|Minimum Order Quantity:||300, 000 amps|
|Packaging Details:||10 x 10amps/box|
|Payment Terms:||L/C, T/T|
|Supply Ability:||one million amps per day|
|Product:||Artemether Injection||Specification:||1ml: 80mg, 0.5ml:40mg|
|Standard:||BP, USP||Packing:||10 X 10amps/box|
Antimalarial Agent Artemether Injection Dosage Antimalarial Medication 80mg/1ml 40mg/0.5ml
Product : Artemether Injection
Specification : 1ml: 80mg, 0.5ml:40mg
Standard : BP, USP
Packing : 10 x 10amps/box
Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of Plasmodium spp. and may be used to treat infections caused by P. falciparum and unidentified Plasmodium species, including infections acquired in chloroquine-resistant areas.
Artemether and lumefantrine combination therapy is indicated for the treatment of acute uncomplicated malaria caused by Plasmodium falciparum, including malaria acquired in chloroquine-resistant areas. May also be used to treat uncomplicated malaria when the Plasmodium species has not been identified. Indicated for use in adults and children greater than 5 kg.
Injection: 3.2 mg/kg intra muscularly as a loading dose, followed by 1.6 mg/kg daily until oral therapy.
In the body, artemether is metabolized into the active metabolite metabolite dihydroartemisinin. The drug works against the erythrocytic stages of P. falciparum by inhibiting nucleic acid and protein synthesis. Artemether is administered in combination with lumefantrine for improved efficacy. Artemether has a rapid onset of action and is rapidly cleared from the body. It is thought that artemether provides rapid symptomatic relief by reducing the number of malarial parasites. Lumefantrine has a much longer half life and is believed to clear residual parasites.
Mechanism of action
Involves an interaction with ferriprotoporphyrin IX (“heme”), or ferrous ions, in the acidic parasite food vacuole, which results in the generation of cytotoxic radical species. The generally accepted mechanism of action of peroxide antimalarials involves interaction of the peroxide-containing drug with heme, a hemoglobin degradation byproduct, derived from proteolysis of hemoglobin. This interaction is believed to result in the formation of a range of potentially toxic oxygen and carbon-centered radicals.